VENTURE 17             - Private Education for the Medical Arts and Sciences
RSS Follow Become a Fan

Delivered by FeedBurner


Recent Posts

CORONA VIRUS UPDATES
Migraine Therapy Update
NET NEUTRALITY
LEUKEMIA, THE PARADIGM MIRACLE
MIGRAINES IN CHILDREN

Most Popular Posts

Stem Cell Research Stopped?
New Advancements in the Understanding and Treatment of Parkinson’s Disease
Is My Headache a Migraine?
Crohns Disease and Today's Athlete
Neurology Update: Normal Pressure Hydrocephalis

Categories

Arts and Photography
Business
Clinical Update
Education
Education and Political Action
Medical Advise
Medical History
Medical Law
Medical Opinion
Personal Fitness
Political Comment
Psychology
Recipes
Science Update
Social Comment
Special Post
Student Post
powered by

THE SEARCHLIGHT MESSENGER

Clinical Update

CORONA VIRUS UPDATES







50PCS 3 ply black disposable face shield from Amazon

















Migraine Therapy Update


The CGRP Receptor and Migraines. 

A video review from Eli Lilly. Venture 17 has no economic relationship with Eli Lilly. This video is for educational purposes only.

Click this image to view the video.

CGRP

























Venetoclax Shows Promise in Acute Myelogenous Leukemia

Venetoclax monotherapy appears to improve outcomes in some patients with acute myelogenous leukemia (AML), according to a phase 2, single-arm study.

"This study included patients that were in categories that are difficult to treat - relapsed, refractory, and/or elderly and deemed medically unfit to receive induction therapy," Dr. Anthony Letai from Dana-Farber Cancer Institute in Boston told Reuters Health by email.

"The fact that some of these patients had leukemias that were relapsed or refractory to very tough regimens, including regimens that require multi-week inpatient hospital stays, but nonetheless responded to an oral outpatient therapy taken once a day was a very interesting result," he said.

Von Willebrand Disease Phase 3 Trial Reports 100% Bleed Control

Von Willebrand disease (VWD) is an inherited, genetically and clinically heterogeneous hemorrhagic disorder caused by a deficiency or dysfunction of the protein called Von Willebrand factor (VWF). This protein is a necessary step in the coagulation cascade, but also involved in the initiation of platelet aggregation for proper blood clotting.

Consequently, defective VWF interaction between platelets and the vessel wall impairs primary hemostasis. Von Willibrand factor circulates in blood plasma at concentrations of approximately 10 mg/mL.

Maintenance of Certification: Doctors Strike Back


Doctors Strike Back

Underlying much of the controversy surrounding Maintenance of Certification (MOC), is the question of how much, or even whether, the process as currently structured actually improves physician performance and/or patient outcomes.
 
On February 3, 2015, many physicians received a surprising email from Richard Baron, MD, MACP, president and chief executive officer of theAmerican Board of Internal Medicine(ABIM). Referring to the board’s controversial maintenance of certification (MOC) program, Baron wrote, “ABIM clearly got it wrong.